Speaker illustration

Miss Line Melgaard

Aalborg University Hospital, Aalborg (Denmark)

Line Melgaard MSc, PhD graduated from the University of Aalborg in 2013 with a master degree in Medicine with Industrial Specialization, which combines medicine, pharmacology, and research. She received a PhD-degree from Aalborg University in 2016 (title: “Thromboembolic risk in heart failure patients without atrial fibrillation”). During her PhD, she used Danish nationwide registry data to investigate predictors of ischemic stroke and thromboembolic events in a heart failure population without diagnosed atrial fibrillation. She is currently employed at the Thrombosis and Drug Research Unit, Department of Cardiology, Aalborg University Hospital in Denmark and her research interests include heart failure, atrial fibrillation, and thrombosis. At the ESC congress in 2015, she won the “Young Investigators Award – Thrombosis” for her research within stroke risk schemes in heart failure patients with/without atrial fibrillation.

Thromboembolic risk in non-anticoagulated atrial fibrillation patients with valvular heart disease and low CHA2DS2-VASc scores: Are these patients truly low risk of stroke?

Event: ESC CONGRESS 2020 - The Digital Experience

Topic: Stroke in Atrial Fibrillation

Session: Atrial Fibrillation ePosters

Thumbnail

Predictors of thromboembolism in patients with atrial fibrillation and valvular heart disease according to the EHRA classification: beyond mitral stenosis and mechanical prosthetic heart valves

Event: ESC CONGRESS 2019

Topic: Stroke in Atrial Fibrillation

Session: Adverse outcomes in atrial fibrillation: can they be prevented?

Thumbnail

Thromboembolic risk in patients with atrial fibrillation and valvular heart disease according to the EHRA Type 2 definition: beyond mitral stenosis and mechanical prosthetic heart valve.

Event: EHRA 2019

Topic: Stroke in Atrial Fibrillation

Session: Late-breaking trials 3

Thumbnail

This platform is supported by

logo Novo Nordisk